@nataliejohnson , Hi there, i would like to expose you some info;

Facts

Human papillomavirus (HPV) is a sexually transmitted pathogen that causes anogenital and oropharyngeal disease in males and females. Persistent viral infection with high-risk HPV genotypes causes virtually all cancers of the cervix. The high-risk HPV genotypes (or "types") 16 and 18 cause approximately 70 percent of all cervical cancers worldwide, and types 31, 33, 45, 52, and 58 cause an additional 20 percent. HPV types 16 and 18 also cause nearly 90 percent of anal cancers and a significant proportion of oropharyngeal cancer, vulvar and vaginal cancer, and penile cancer. HPV types 6 and 11 cause approximately 90 percent of anogenital warts.

Three different vaccines, which vary in the number of HPV types they contain and target, have been clinically developed, although not all are available in all locations:
Quadrivalent HPV vaccine (Gardasil) targets HPV types 6, 11, 16, and 18.
9-valent vaccine (Gardasil 9) targets the same HPV types as the quadrivalent vaccine (6, 11, 16, and 18) as well as types 31, 33, 45, 52, and 58.
Bivalent vaccine (Cervarix) targets HPV types 16 and 18.

Vaccination with 9-valent, quadrivalent, or bivalent HPV vaccine provides a direct benefit to female recipients by safely protecting against cancers that can result from persistent HPV infection. This preventive effect is most notable and best studied with cervical cancer, which is one of the most common female cancers worldwide. HPV types 16 and 18, which are targeted by all three HPV vaccines, cause approximately 70 percent of all cervical cancers worldwide

Safety

All vaccines use virus-like particles (VLPs), which mimic the viral capsid. VLPs do not contain genetic material and are produced in biologic systems, which have well-established safety records. All HPV vaccines have documented safety in large clinical trials, and extensive post-licensure data (following approval and clinical use) on the quadrivalent vaccine support this safety profile.

Data from both registration trials and post-licensure safety surveillance systems demonstrate that the vaccine is safe and well tolerated apart from mild injection site reactions. Postvaccination syncopal events have emerged as a potential serious adverse effect, although it does not appear unique to HPV vaccination, since syncope after vaccination occurs with other vaccines administered to adolescents.

Evidence

What was the question of this study?? - To summarize reports to the Vaccine Adverse Event Reporting System (VAERS) following receipt of qHPV.

Design of the study? Case controls – that is used in medicine to prove associations.

How much people was in this study? Between June 2006 and December 2008, With more tan 23 million qHPV doses distributed in the United States as of December 31, 2008.

Results? - VAERS received 12 424 reports of AEFIs (adverse events following immunization) following qHPV distribution, a rate of 53.9 reports per 100,000 doses distributed.

• A total of 772 reports (6.2% of all reports) described serious AEFIs, including 32 reports of death. The reporting rates per 100,000 qHPV doses distributed were 8.2 for syncope; 7.5 for local site reactions; 6.8 for dizziness; 5.0 for nausea; 4.1 for headache; 3.1 for hypersensitivity reactions; 2.6 for urticaria; 0.2 for venous thromboembolic events, autoimmune disorders, and Guillain-Barrésyndrome; 0.1 for anaphylaxis and death; 0.04 for transverse myelitis and pancreatitis; and 0.009 for motor neuron disease.

Conclusions - Most of the AEFI rates were not greater than the background rates compared with other vaccines.

Notes

• There were 32 VAERS reports of death following qHPV vaccination. Causes of death included 4 unexplained deaths, 2 cases of diabetic ketoacidosis (1 complicated by pulmonary embolism), 1 case related to prescription drug abuse, 1 case of juvenile amyotropic lateral sclerosis, 1 case of meningoencephalitis (Neisseria meningitidisserogroup B), 1 case of influenza B viral sepsis, 3 cases of pulmonary embolism (1 associated with hyperviscosity due to diabetic ketoacidosis), 6 cardiac-related deaths (4 arrhythmias and 2 cases of myocarditis), and 2 cases due to idiopathic seizure disorder.

Reported deaths with available records, autopsy reports, or death certificates describe causes other than recent vaccination.

i do this because as a doctor, i have the responsibility to give the right information to the patients. Now i´m with you, we need more information and longer trials to know why some few deaths are presented. But until today there is no information to recommend NOT accepting this vaccine. The later conclusion is up to you.

---

References

http://www.uptodate.com/contents/human-papillomavirus-hpv-vaccine-beyond-the-basics

Barbara A. Slade, MD, MS; Laura Leidel, RN, FNP-C, MPH; Claudia Vellozzi, MD. Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine. JAMA. 2009;302(7):750-757. doi:10.1001/jama.2009.1201